Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson’s disease
Heliyon. 2020-12-01; 6(12): e05771
DOI: 10.1016/j.heliyon.2020.e05771
Lire sur PubMed
Delamarre A(1)(2), MacSweeney C(3), Suzuki R(3), Brown AJ(3), Li Q(4), Pioli EY(4), Bezard E(1)(2)(4).
Author information:
(1)Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, 33000, France.
(2)Centre National de la Recherche Scientifique, Institut des Maladies Neurodégénératives, Bordeaux, 33000, France.
(3)Sosei Heptares, Cambridge, CB21 6DG, United Kingdom.
(4)Motac Neuroscience, Macclesfield, SK10 4TF, United Kingdom.
Background: Gastrointestinal (GI) and metabolic function are frequently altered in Parkinson’s disease (PD). Although enteric nervous system anatomopathological alterations have previously been reported in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of PD, the resulting gastric emptying and intestinal permeability functional parameters are unknown. The current exploratory study was, thus, designed to investigate these GI functional factors and insulin resistance in the MPTP-treated monkey.
Methods: Eight rhesus macaque monkeys (4 controls and 4 MPTP-treated) received the oral acetaminophen absorption test to measure gastric emptying, the oral FITC-dextran absorption test to investigate intestinal permeability, and the intravenous glucose tolerance test to assess insulin resistance. Constipation was evaluated using the Bristol stool scale.
Results: None of the tests, acetaminophen absorption, FITC-dextran absorption or glucose tolerance, showed a difference between control and MPTP-treated monkeys. MPTP-treated monkeys did present signs of transit acceleration.
Conclusion: While the MPTP monkey model reliably displays motor and certain non-motor symptoms of PD, the current study did not demonstrate the GI symptoms associated with PD.